Europe
Health
Female CEOs

Mylan

$19.64
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.57 (-2.82%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Mylan and other stocks, options, ETFs, and crypto commission-free!

About

Mylan N.V. Ordinary Shares, also called Mylan, is a pharmaceutical healthcare company. Read More The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Employees
35,000
Headquarters
Hatfield, Hertfordshire
Founded
1961
Market Cap
10.14B
Price-Earnings Ratio
42.70
Dividend Yield
0.00
Average Volume
5.29M
High Today
$20.07
Low Today
$19.63
Open Price
$20.05
Volume
2.56M
52 Week High
$42.50
52 Week Low
$19.40

Collections

Europe
Health
Female CEOs
Pharmaceutical
UK
Technology
Manufacturing

News

Seeking AlphaMay 17

Assessing What Happens If Fitch Sacks Mylan

Mylan corporate logo. Source: Bloomberg Mylan's (NASDAQ:MYL) revenue and operating income are in rapid decline. Its $14 billion debt load makes the decline even more problematic. Fitch Ratings recently revised Mylan's outlook to negative and implied a downgrade could leave the company's debt with a junk rating: Fitch Ratings has affirmed Mylan's long-term Issuer Default Rating ("IDR") at 'BBB-' and its short-term IDR at 'F3'. The Rating Outlook is revised to Negative from Stable. The ratings apply to appr...

364
ReutersMay 15

In win for Mylan, appeals court axes patents on arthritis drug Vimovo

A federal appeals court on Wednesday eased the way for Mylan NV and other generic drug companies to launch a generic version of Horizon Pharma PLC and Nuvo Pharmaceutical Inc’s arthritis drug Vimovo.

316
Yahoo FinanceMay 15

The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer

For Immediate Release Chicago, IL –May 15, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Teva Pharmaceutical Industries Ltd. TEVA, Mylan MYL, Novartis NVS and Pfizer PFE. Here are highlights from Tuesday’s Analyst Blog: Scroll to continue with content Ad Generic Drugmakers Face Antitrust Suit Alleging Price...

13

Earnings

$0.80
$1.01
$1.22
$1.43
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
$0.80 per share
Actual
$0.82 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.